💊 药物 A-Z 🧬 靶点 🛠 工具 📚 指南
全部药物 药物分类 治疗领域 不良反应
指南 术语表 时间轴
药物比较 药物旅程 药物家族
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tenofovir Alafenamide Fumarate

CHEMBL2364637 Phase 4 已批准 Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
1069.0 g/mol
LogP
—
Phase
4

Tenofovir alafenamide fumarate is the fumarate salt form of tenofovir alafenamide (TAF), a prodrug NRTI that is converted intracellularly to tenofovir diphosphate to inhibit HIV-1 and HBV reverse transcriptase. See tenofovir-alafenamide for complete pharmacological details. This salt form is used in numerous fixed-dose combination antiretroviral products.

分子量

1069.0000 g/mol

TPSA

362.00 Ų

治疗领域

Cardiovascular Disease Rheumatoid Arthritis Osteoporosis Generalized Anxiety Disorder Multiple Sclerosis Non-Alcoholic Fatty Liver Disease Obesity Hypertension HIV/AIDS Hepatitis C Tuberculosis Heart Failure

作用机制

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

二维结构

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)Oc1ccccc1.CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)Oc1ccccc1.O=C(O)/C=C/C(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/2C21H29N6O5P.C4H4O4/c2*1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27;5-3(6)1-2-4(7)8/h2*5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24);1-2H,(H,5,6)(H,7,8)/b;;2-1+/t2*15-,16+,33+;/m11./s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C46H62N12O14P2

                    

                    
                    

                        
HBD / HBA

                        
6 / 24

                    

                    
                    

                        
可旋转键数

                        
26

                    

                    
                    
                    

                        
重原子数

                        
74

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
常见问题

                

                    
                    

                        
                        

                            
Tenofovir alafenamide fumarate is the fumarate salt form of tenofovir alafenamide (TAF), a prodrug NRTI that is converted intracellularly to tenofovir diphosphate to inhibit HIV-1 and HBV reverse transcriptase. See tenofovir-alafenamide for complete pharmacological details. This salt form is used in numerous fixed-dose combination antiretroviral products.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Tenofovir Alafenamide Fumarate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2364637.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 71492247.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
医疗免责声明

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.